StockData
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. (EBS) income statement

EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.50−0.11 (-1.96%)

Close on Nov 18, 2026Market cap $282.00MP/E –Yield –

Emergent BioSolutions Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
48.4%
Operating margin
-27.7%
Net margin
-40.2%
Return on equity, FY2025
10.5%

Financial strength

Current ratio
4.58
Debt to equity
1.62
Debt to assets
51.0%
Cash to current liabilities
144.0%

Valuation

P/E ratio
–
Price to sales
0.43
Price to book
0.90
Dividend yield
–

See a number that looks wrong?